Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiati

on of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia USA - English USA - English News provided by Vaderis Therapeutics AG Aug 11, 2026, 07:00 ET Share this article Share to X Share this article Share to X $152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the company with capital needs through potential U.S. regulatory approval of engasertib Marks the company's transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib, a once daily oral medication, in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT) BASEL, Switzerland and LINCOLNSHIRE, Ill. 11, 2026 /PRNewswire/ -- Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million Series B financing and initiation of HEROIC, the company's global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT). Together, these milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically developed for people living with HHT, a rare genetic vascular disorder that currently has no approved treatment options worldwide.